Delivery Order SPE2DB20D1004-SPE2DB25FNKFH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials with a ceiling value of $2,878.11. This competitively awarded, firm fixed-price delivery order is set to be completed by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value pharmaceutical procurement under the company's existing...
- The Defense Logistics Agency awarded a delivery order valued at $3,633.25 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract utilizes a firm fixed price arrangement with an ultimate completion date of August 8, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $1,957.32. This competitive, firm fixed-price delivery order is set to be completed by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under a larger contract vehicle, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $2,838.00 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract was competitively awarded on August 27, 2025, with a firm fixed price structure and an ultimate completion date of August 28, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order carries no set-aside designation,...
- The Defense Logistics Agency awarded a $31,772.81 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with an ultimate completion date of July 17, 2025. This competitive award, issued on July 16, 2025, carries a firm fixed price and involves no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary distribution and pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $41,578.22 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract, awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This award represents a competitive...
- The Defense Logistics Agency awarded a $9,214.56 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and a completion date of September 16, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $6,602.38 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with an ultimate completion date of August 18, 2025. The contract employs firm fixed pricing and carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen's place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $1,758.99. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,407.97 for Ozempic 1 mg/dose (4 mg/3 mL) vials on June 4, 2025, with a completion date of June 5, 2025. This firm fixed-price, competitively awarded delivery order represents a small-value pharmaceutical transaction executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The place of performance is AmerisourceBergen's corporate...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNKFHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,786.99 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies a comprehensive portfolio of brand-name and generic medications, vaccines, and medical devices to support military and veteran healthcare systems globally. The parent IDC serves as a flexible procurement vehicle enabling the company to fulfill pharmaceutical needs across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 8/19/25 |